OUR INNOVATIONS FOR UNMET MEDICAL NEEDS
We focus on solutions for unmet medical needs.
There are examples of areas where we leverage our strengths to make a significant difference to both professional and patient communities.
We are developing innovations to treat the rapidly progressive neurological disease amyotrophic lateral sclerosis (ALS). Another firm in our corporate organization is one of the 10 largest pharmaceutical companies in the field of immunology.
The scientific strengths of our parent, Mitsubishi Tanabe Pharma Corporation, are diverse and deep, with a pipeline driven by a sense of speed and the goal of being first to deliver differentiated value.
The Mitsubishi Tanabe Pharma Corporation Group believes that it can contribute to the progress of medical science and medical treatment by increasing transparency in clinical trial information. Based on this principle, MTPC Group will disclose information, such as summaries of clinical trial information, clinical trial results, and clinical trial data, from clinical trials conducted by the MTPC Group in a timely and appropriate manner in accordance with the Principles laid out by the industry associations and the policy referenced in the link below.